Maharashtra Chief Minister Uddhav Thackeray has written a letter to the Centre, saying the number of active caseload of COVID-19 in the state is expected to double in the next 15 days. Maharashtra is expecting its active caseload to reach 11.9 lakh by April 30, compared to the current active caseload of 5.64 lakh, Thackeray said on Wednesday in the letter addressed to Prime Minister Narendra Modi. He also said the medical oxygen requirement in the state is projected to reach 2,000 metric tonnes per day by April-end from the present consumption of 1,200 MT per day. Citing logistical hurdles in the transportation of liquid medical oxygen from neighbouring states, Thackeray also sought permission under the National Disaster Management Act to airlift oxygen from steel plants in eastern and southern parts of the country.
drug against Covid-19 | Media for Freedom mediaforfreedom.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mediaforfreedom.com Daily Mail and Mail on Sunday newspapers.
Saturday, 10 April 2021, 5:01 pm
Should not a medicine (Remdesivir) that has shown
lifesaving effect in certain cases of Covid-19 be made
available to all those who need it without delay? Even if
Big Pharma has a patent, there are provisions in the global
trade treaties that allow governments to issue compulsory
licenses to such a lifesaving drug, and keep people over
profit. This is why medical experts are demanding
governments to use compulsory licensing for generic
production of such a drug to help save
lives.
Compulsory licensing is one of the key public
health and social justice safeguards that allows governments
Experts demand compulsory licensing for generic production of a drug against COVID-19 modernghana.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernghana.com Daily Mail and Mail on Sunday newspapers.
Uptrend in oppositions could spell costly delays for Indian patent applicants Straw man oppositions are attracting increased scrutiny from Indian patent applicants as well as the courts - best practices in drafting and prosecution can help mitigate the risks.
The past two years have seen a surge in oppositions filed against patent applications in India. The increase comes as the patent office publishes more filings than ever and Indian courts continue to handle high-profile global disputes. The strategic value of patent oppositions make this an important trend for IP owners to follow.
Facing a pre-grant opposition can significantly extend the time to grant, even if the objection fails. This is important because the already lengthy wait for a granted patent in India can greatly reduce the time a rightsholder has to enforce their exclusivity in the market.